Experts examine cutting-edge treatments, clinical trial results, and personalized approaches for managing relapsed/refractory multiple myeloma, focusing on novel therapies like CAR T-cells, bispecific antibodies, and their optimal sequencing to improve patient outcomes.
EP. 1: Treatment Strategies in Relapsed Refractory Multiple Myeloma
Panelists discuss how novel therapeutic approaches and combination regimens are reshaping the landscape of treatment for patients with relapsed/refractory multiple myeloma, offering new hope for improved outcomes and quality of life.
EP. 2: Ide-Cel: Real-World Outcomes for Relapsed Refractory Multiple Myeloma
Panelists discuss how ide-cel, a CAR T-cell therapy, demonstrates promising real-world outcomes in patients with relapsed/refractory multiple myeloma, potentially offering a valuable treatment option for this challenging patient population.
EP. 3: KarMMa-3: Ide-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
Panelists discuss how the KarMMa-3 trial results demonstrate superior efficacy of ide-cel compared to standard of care therapies in patients with relapsed/refractory multiple myeloma, potentially establishing a new benchmark for treatment in this setting.
EP. 4: CARTITUDE-4: Cilta-cel vs Standard of Care Therapies in Relapsed Refractory Multiple Myeloma
Panelists discuss how the CARTITUDE-4 trial results show cilta-cel's superior efficacy over standard of care therapies in treating relapsed/refractory multiple myeloma, potentially reshaping treatment paradigms for this patient population.